More light for Clinuvel
Tuesday, 23 September, 2008
Clinuvel Pharmaceuticals (ASX: CUV) has begun phase II trials of its photoprotective drug afamelanotide (CUV1657) in patients undergoing photodynamic therapy (PDT).
The trial is being conducted in a Parisian hospital and will extend to multiple health-care centres in France.
The first four of an anticipated 30 patients have been dosed, and results are expected within 12 months.
PDT is used to eradicate pre-malignant lesions of the oesophagus and as a palliative therapy in bile duct cancer. It involves administration of porfimer sodium, a photosensitiser, and a targeted light source.
One side effect is phototoxicity, with patients unable to tolerate UV light. Clinuvel anticipates that afamelanotide may offer a photoprotective effect.
Clinuvel is currently in Phase III trials of CUV1657 in erythropoietic protoporphyria (EPP), or abnormal sun sensitivity.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
